Vulvar Cancer clinical trials

Explore recruiting vulvar cancer clinical trials.

Recruiting vulvar cancer studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Vulvar Cancer trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Pembrolizumab plus Lenvatinib in vulvar cancer patients: The prospective, multi-cohorts and multicentre, phase 2 MITO VULVA-01 study.

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

GROINSS-V III; Groningen International Study on Sentinel node in Vulvar cancer III – a prospective phase 2 treatment trial

Netherlands, France, Sweden, Belgium

Therapeutic exploratory (Phase II) EU CTIS Study details

NON-IV: Neo-adjuvant peritumOral immuNotherapy In Vulvar cancer

Netherlands

Human Pharmacology (Phase I)- Other EU CTIS Study details

A Registry-Based Extension of Protocol V503-001 in Countries with Centralized Cervical Cancer Screening Infrastructures to Evaluate the Long-Term Effectiveness, immunogenicity, and Safety of Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine as Administered to 16- to 26- Year- Old Women.

Norway, Sweden, Denmark

Therapeutic confirmatory (Phase III) EU CTIS Study details

Electrochemotherapy with Carboplatinum plus Bleomycin versus Bleomycin alone in vulvar cancer: the ElechtraPlatinum Study. A Randomized Controlled Trial

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

Pembrolizumab in combination with lenvatinib in patients with recurrent, persistent, metastatic or locally advanced vulvar cancer not amenable to curative surgery or radiotherapy

Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

Vulvar Cancer trials by city

Vulvar Cancer in Toronto Vulvar Cancer in Vancouver Vulvar Cancer in Montreal Vulvar Cancer in Calgary Vulvar Cancer in Edmonton Vulvar Cancer in Ottawa Vulvar Cancer in Winnipeg Vulvar Cancer in Quebec City Vulvar Cancer in Hamilton Vulvar Cancer in Kitchener Vulvar Cancer in London Vulvar Cancer in Halifax Vulvar Cancer in New York Vulvar Cancer in Los Angeles Vulvar Cancer in Chicago Vulvar Cancer in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease